Takeda Pharmaceuticals will conduct clinical trials in India in an attempt to enhance innovation, increase the launch of cancer drugs, and integrate global research.

Takeda Pharmaceuticals, the Japanese drug organization, is considering establishing global clinical trials in India to expedite the launch of drugs there. The company is investing in innovation, research and digital transformation in order to consolidate its presence in India, which the company views as a strategic growth market.

Annapurna Das, General Manager of the Takeda operations in India, talked of the assessment the pharmaceuticals company is undertaking to team up with local academia, healthcare providers and technology firms to access the emerging clinical trial ecosystem in India. She noted that India has a special opportunity, as there is a diverse pool of patients, economics of scale, or cost advantage and a growing hospital to cater to it.

Takeda Pharmaceuticals plans to bring to market superior therapies in oncology, neuroscience, GI health, and inflammation, with a lung cancer drug this year. It is also co-venturing with Biological E. to produce a dengue vaccine that is awaiting regulatory clearance.

In another move to advance its innovation agenda, the company opened a center in Bengaluru that houses 500 specialists in AI, data science, and engineering but will grow to 750 employees. This is a center that assists Takeda in its digital transformation worldwide.

As the economic value of the clinical trials market in India is estimated to reach 2 billion dollars by 2030, Takeda Pharmaceuticals will ensure access to local prowess and increase the number of patients who have access to innovative medical care.